Assenagon Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Assenagon Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.18M	Buy	124,569 +60,886	+96%	+$3.5M	0.01%	592
2026 Q1	$3.86M	Sell	63,683 -971	-2%	-$56.6K	0.01%	639
2025 Q4	$3.49M	Buy	64,654 +715	+1%	+$34.4K	﹤0.01%	715
2025 Q3	$2.88M	Sell	63,939 -230	-0.4%	-$10.7K	﹤0.01%	751
2025 Q2	$2.97M	Sell	64,169 -869	-1%	-$42.7K	﹤0.01%	673
2025 Q1	$3.97M	Buy	65,038 +869	+1%	+$50.7K	0.01%	581
2024 Q4	$3.63M	Sell	64,169 -22	-0%	-$1.23K	0.01%	771
2024 Q3	$3.32M	Buy	64,191 +7,245	+13%	+$340K	0.01%	819
2024 Q2	$2.36M	Sell	56,946 -43,876	-44%	-$1.96M	0.01%	843
2024 Q1	$5.47M	Buy	100,822 +2,428	+2%	+$124K	0.01%	586
2023 Q4	$5.05M	Buy	98,394 +3,313	+3%	+$174K	0.01%	635
2023 Q3	$5.52M	Buy	95,081 +3,907	+4%	+$239K	0.02%	554
2023 Q2	$5.83M	Buy	91,174 +59	+0.1%	+$3.96K	0.02%	466
2023 Q1	$6.32M	Buy	91,115 +5,406	+6%	+$381K	0.02%	511
2022 Q4	$6.17M	Sell	85,709 -3,560	-4%	-$268K	0.02%	493
2022 Q3	$6.35M	Buy	89,269 +36,349	+69%	+$2.64M	0.02%	432
2022 Q2	$4.08M	Buy	52,920 +7,207	+16%	+$549K	0.02%	607
2022 Q1	$3.34M	Buy	45,713 +22,509	+97%	+$1.51M	0.01%	656
2021 Q4	$1.45M	Sell	23,204 -824	-3%	-$48.3K	﹤0.01%	937
2021 Q3	$1.42M	Buy	24,028 +18,107	+306%	+$1.19M	﹤0.01%	810
2021 Q2	$396K	Sell	5,921 -705	-11%	-$46K	﹤0.01%	1069
2021 Q1	$418K	Sell	6,626 -18,388	-74%	-$1.14M	﹤0.01%	1053
2020 Q4	$1.55M	Buy	25,014 +6,189	+33%	+$381K	0.01%	584
2020 Q3	$1.14M	Sell	18,825 -7,118	-27%	-$428K	0.01%	760
2020 Q2	$1.52M	Hold	25,943	–	–	0.01%	675
2020 Q1	$1.45M	Sell	25,943 -58,884	-69%	-$3.6M	0.01%	431
2019 Q4	$5.45M	Buy	84,827 +29,503	+53%	+$1.69M	0.03%	231
2019 Q3	$2.81M	Sell	55,324 -3,400	-6%	-$160K	0.02%	340
2019 Q2	$2.66M	Sell	58,724 -2,907	-5%	-$135K	0.02%	443
2019 Q1	$2.94M	Sell	61,631 -5,141	-8%	-$256K	0.03%	416
2018 Q4	$3.47M	Buy	66,772 +19,159	+40%	+$1.03M	0.04%	315
2018 Q3	$2.96M	Buy	47,613 +1,772	+4%	+$105K	0.03%	427
2018 Q2	$2.54M	Buy	45,841 +32,134	+234%	+$1.74M	0.03%	298
2018 Q1	$867K	Sell	13,707 -2,239	-14%	-$144K	0.01%	421
2017 Q4	$977K	Buy	15,946 +4,885	+44%	+$306K	0.01%	545
2017 Q3	$705K	Sell	11,061 -4,267	-28%	-$249K	0.01%	396
2017 Q2	$854K	Buy	15,328 +4,083	+36%	+$222K	0.02%	159
2017 Q1	$612K	Buy	+11,245	New	+$617K	0.01%	198

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Assenagon Asset Management's BMY Position: Q2 2026 in Review

Assenagon Asset Management increased its Bristol-Myers Squibb (BMY) stake by 96% in Q2 2026, buying an estimated $3.5M and bringing the position to 124,569 shares worth $7.18M. The position accounts for 0.01% of the portfolio, ranked #592.

Assenagon Asset Management first reported a position in BMY in Q1 2017 and has held it in 38 quarters since. 830 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Assenagon Asset Management held 124,569 shares of Bristol-Myers Squibb worth $7.18M as of Q2 2026.
Assenagon Asset Management bought 60,886 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.5M.
Bristol-Myers Squibb made up 0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #592 holding.
Assenagon Asset Management first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 38 quarters since.
830 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.